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Different viruses trigger pattern recognition receptor systems, such as Toll-like receptors or cytosolic RIG-I like helicases (RLH),
and thus induce early type I interferon (IFN-I) responses. Such responses may confer protection until adaptive immunity is
activated to an extent that the pathogen can be eradicated. Interestingly, the same innate immune mechanisms that are relevant
for early pathogen defense have a role in ameliorating experimental autoimmune encephalomyelitis (EAE), a rodent model of
human multiple sclerosis. We and others found that mice devoid of a component of the IFN-I receptor (Ifnar1/) showed
signiﬁcantly enhanced autoimmune disease of the central nervous system (CNS). A detailed analysis revealed that in wild-type
mice IFN-I triggering of myeloid cells was instrumental in reducing brain damage. A more recent study indicated that similar to
Ifnar1/ mice, RLH-signaling-deﬁcient mice showed enhanced autoimmune disease of the CNS as well. Moreover, when
peripherally treated with synthetic RLH ligands wild-type animals with EAE disease showed reduced clinical scores. Under such
conditions, IFN-I receptor triggering of dendritic cells had a crucial role. The therapeutic effect of treatment with RLH ligands
was associated with negative regulation of Th1 and Th17 T-cell responses within the CNS. These experiments are consistent
with the hypothesis that spatiotemporal conditions of, and cell types involved in, disease-ameliorating IFN-I responses differ
signiﬁcantly, depending on whether they were endogenously induced in the context of EAE pathogenesis within the CNS or upon
therapeutic RLH triggering in the periphery. It is attractive to speculate that RLH triggering represents a new strategy to treat
multiple sclerosis by stimulating endogenous immunoregulatory IFN-I responses.
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During the last decade a detailed understanding of molecular mechan-
isms associated with the recognition of pathogens has been achieved.
In addition to Toll-like receptors, retinoic acid-inducible gene I
(RIG I)-like helicases (RLH), nucleotide-binding oligemerization
domain-like receptors, C type lectin-like receptors and intracellular
DNA receptors, probably other, not-yet-identiﬁed mechanisms exist
that have a role in pathogen recognition.1 Many signaling pathways of
the innate immune system result in the induction of type I interferons
(IFN-I) and other cytokines. IFN-I is of particular interest because it is
induced within hours after infection, often at high quantities, and it
can induce an antiviral state of cells. Virtually all cells of the body
express the IFN-I receptor. Among IFN-I, 1 IFN-beta, more than 10
IFN-alphas and a number of less-dominant subtypes are found.2 In
cell culture, upon infection basically any cell type mounts IFN-I
responses, whereas in vivo certain immune-cell subsets such as
dendritic cells (DCs) and in particular plasmacytoid DCs are impor-
tant IFN-I producers.3
IFN-I responses have a role in pathogen defense on different levels.
Besides IFN-I-stimulated cells being less readily infected, they typically
show enhanced MHC-I expression levels. Especially antigen-present-
ing cells such as DCs show an improved maturation and induce
optimal T-cell responses upon IFN-I receptor engagement.4–6 Further-
more, the functions of other immune cells may be affected in that they
show modiﬁed homing properties7,8 and enhanced or reduced effector
function. It was reported that, upon various infections, antibody
production by B cells,9 as well as T-cell expansion and cytokine
expression critically requires direct IFN-I receptor triggering. In the
context of T-cell stimulations, IFN-I may act as a third signal to
further enhance T-cell expansion.10 Furthermore, IFN-I may exert
anti-tumoral function.11
In addition to its protective effects in many different infectious
diseases, IFN-I responses may also be detrimental12 and confer
immunopathology. With regard to the latter aspect, IFN-I has also
been shown to enhance inﬂammatory processes in different auto-
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www.nature.com/icbimmune diseases, such as systemic lupus erythematosus.13 Never-
theless, local IFN-I induction may as well induce immunoregulation
and reduce inﬂammation, as shown in rheumatoid arthritis and
multiple sclerosis. In this review, the current view of how IFN-beta
treatment affects the disease severity of multiple sclerosis (MS) is
summarized. Furthermore, new insights into the role of IFN-I in the
rodent model of MS, the experimental autoimmune encephalomyelitis
(EAE), are discussed. Finally, new directions of MS treatment strate-
gies are highlighted.
IFN-BETA TREATMENT OF RELAPSING–REMITTING MULTIPLE
SCLEROSIS
MS is an autoimmune demyelinating disease of the central nervous
system (CNS). Disease onset typically occurs in young adults, with
increased incidence in women.14 It is believed that long before clinical
manifestation, inﬂammatory T cells speciﬁc for antigen structures
similar to myelin are activated in the periphery.15 Such cells cross the
blood–brain barrier and move into the CNS, where they induce
inﬂammatory processes.16 Therapeutic approaches available today
primarily aim at modulating or interfering with these immunological
processes. For treatment of relapsing–remitting MS IFN-beta is
licensed as a therapeutic. IFN-beta treatment reduces the frequency
of clinical exacerbations by approximately 35% and delays the
progression of disability.17 However, 30–50% of MS patients do not
respond to IFN-beta treatment.18 This is either associated with
aberrations in the IFN-I signaling cascade19–24 or the presence and/
or induction of IFN-beta-neuralizing antibody responses.25 In parti-
cular, induction of IFN-beta-neutralizing antibody responses consti-
tute a problem that may turn responders into non-responders. The
incidence of the induction of IFN-beta-speciﬁc antibody responses
differs among marketed products and presumably is caused by
aggregates, oxidated products, trace amounts of product-related
impurities and to a lesser extent by differences in the amino-acid
composition and post-translational modiﬁcations of the product.26
Considering that IFN-beta treatment may be associated with the
induction of adverse effects such as ﬂu-like symptoms, potential
liver damage and psychiatric side effects,27 biomarkers that
discriminate responders and non-responders even before initiation
of the IFN-beta treatment would be helpful; however, these are not yet
available.
Although Epstein–Barr virus infection together with a genetic
predisposition may be a certain risk factor for disease development,
so far the etiology of MS is largely unclear.28 As patients’ materials,
such as blood and brain samples, are not easily assessable, knowledge
about how IFN-beta treatment affects autoimmune inﬂammation
within the CNS is limited.29 In the human system, IFN-beta induces
a Th2 shift. This notion is supported by experimental data indicating
that upon IFN-beta treatment myelin basic protein-reactive human
T-cell clones show reduced activity and a Th2 shift.30 Similarly, upon
in vitro IFN-beta stimulation of peripheral blood mononuclear cells
and after IFN-beta treatment of healthy volunteers or MS patients,
enhanced IL-10 expression was detected.31 On the other hand, in 60%
of MS patients treated with IFN-beta, enhanced percentages of
proinﬂammatory Th1 cells were observed that produced IFN-
gamma,32 indicating that IFN-beta may also induce proinﬂammatory
pathways. In more recent studies it was veriﬁed that under IFN-beta
treatment not only anti-inﬂammatory but also Th1-associated gene
signatures were found.33,34 With the discovery of a new inﬂammatory
Th subset, Th17 cells, several IFN-beta-mediated effects also on Th17
have been found. Elevated levels of IL-17 have been reported in
peripheral blood mononuclear cells, cerebrospinal ﬂuid and active
CNS lesions of MS patients.35,36 IFN-beta enhances activation-induced
apoptosis in Th17 but not in Th1 cells. This can be explained by the
enhanced IFN-I receptor expression levels in Th17 cells compared with
Th1 cells.37 A direct IFN-beta treatment of naive CD4+CD45RA+ T
cells cultured under Th17-polarizing conditions resulted in down-
regulation of RORgc, IL-17A and IL-23R, but upregulation of IL-10
gene expression, and had no effects on the Th1 and Th2-associated
transcription factors T-bet and GATA-3.38 Furthermore, IFN-beta-
stimulated DC showed a reduced IL-23 and IL-1b production and an
enhanced IL-27 secretion.38,39 In remitting–relapsing MS patients
IFN-beta non-responders showed higher IL-17F serum levels than
responders.40 Collectively, data showing IFN-beta effects on Th1 as
well as on Th2 and Th17 cells indicate that in humans the immuno-
modulatory function of IFN-beta treatment cannot simply be
explained by the induction of a Th1/Th17 to Th2 shift, but that
more complex mechanisms have a role.
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS,
A RODENT MODEL OF MULTIPLE SCLEROSIS
For analysis of MS-associated disease mechanisms the EAE in rodents
is a broadly accepted animal model. In order to induce EAE, mice or
rats are immunized subcutaneously with MOG3555 peptide in
Freund’s complete adjuvant (CFA). Typically, 10–15 days later, clinical
signs of CNS autoimmunity manifest that slightly improve with time.
In sterile inﬂammation of the CNS it is generally believed that Th1
and Th17 cells confer disease, while Th2 cells are protective.41 More
recent data suggest that Th1 and Th17 cells concomitantly induce
autoimmunity and confer different pathogenic processes within the
CNS.42,43 Generally, Th17 cells seem to be more plastic compared with
Th1 cells. Th17 cells pass through different phases of differentiation,
including induction, ampliﬁcation and stabilization. Induction is
mediated by TGF-beta and IL-6, whereas ampliﬁcation is mediated
by IL-21, and terminal differentiation and stabilization is conferred by
IL-23.44 Interestingly, none of the known Th17 signature cytokines
including IL-17A, IL-17F, IL-21 and IL-22 have been found to be
mandatory for the development of EAE. Instead, granulocyte macro-
phage colony-stimulating factor that is induced by IL-23 fulﬁlls the
criteria of an encephalitogenic cytokine.45
Upon EAE induction in Ifnar1/ mice that are devoid of the IFN-I
receptor, clinical signs of autoimmunity became apparent with similar
kinetics as observed in wild-type controls.46 Of note, the overall
disease score was signiﬁcantly enhanced in IFN-I receptor-deﬁcient
mice in a manner that even occasional death was observed under
conditions where wild-type mice developed only moderate symptoms.
Furthermore, disease severity remained elevated also at later time
points. These observations were in line with earlier experiments in
which Ifnb/ mice devoid of the IFN-beta gene were used for EAE
studies. In these experiments also Ifnb/ mice showed enhanced
disease and an increased inﬂux of mononuclear cells into the CNS.47
Interestingly, in diseased animals Prinz et al.46 detected enhanced IFN-
beta levels exclusively within the CNS but not in the serum of diseased
wild-type animals. These observations are compatible with the model
that during the course of EAE an IFN-beta response is induced within
the CNS that locally stimulates cells and thus modulates inﬂammatory
processes within inﬂammatory foci. EAE studies in Ifnar1/ mice are
limited by the fact that the IFN-I receptor is expressed basically on all
cells of the body. To study whether T cells, monocytes, neurons or
some other cell type had to be IFN-I-stimulated in order to reduce
disease, mice with a cell type-speciﬁc deletion of the Ifnar1 gene were
generated. This was accomplished by ﬂanking the transmembranic
exon 10 of the Ifnar1 chain by loxP sites in a manner that upon
IFN-I and autoimmunity in the CNS
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resulted in a truncated Ifnar1 chain devoid of the transmembranic and
cytoplasmatic signaling domain.7 Such Ifnar1ﬂ/ﬂ mice carrying two
conditional alleles showed a similar IFN-I signaling as compared with
wild-type mice, whereas conditional mice carrying two alleles with a
deleted exon 10 showed an defective IFN-I signaling as observed in
Ifnar1/ mice.7 Analysis of mice with a cell type-speciﬁc IFN-I
receptor deletion revealed that IFN-I receptor engagement neither of
T cells nor of neurons had a role. Instead, IFN-I receptor signaling of
myeloid cells comprising monocytes, macrophages, microglia and
granulocytes was critically involved in amelioration of the overall
disease score46 (for a schematic depiction, see Figure 1a). A detailed
analysis revealed that IFN-beta stimulation of monocytes reduced
lipopolysaccharide (LPS)-induced chemokine production. Further-
more, in mice with a myeloid cell-speciﬁc Ifnar1 deletion, peripheral
myeloid cells showed an overall activated phenotype as also demon-
strated by enhanced MHC-II expression.
Similar to the observation in humans, exogenously administered
IFN-beta can suppress EAE in wild-type mice.48,49 In this context, it is
interesting that IFN-beta treatment signiﬁcantly attenuated the pro-
gression of EAE symptoms in Th1-induced EAE, whereas the symp-
toms of Th17-induced EAE were exacerbated.40 IFN-I can directly
inhibit TGF-beta/IL-6-induced Th17 development. This is demon-
strated by the fact that IFN-I receptor deﬁciency resulted in elevated
numbers of encephalitogenic Th17 cells.50 The ﬁnding that LPS-
stimulated bone marrow-derived macrophages or DC devoid of IFN-
I receptor showed a defective IL-27 production51 suggested that upon
EAE induction in Ifnar1/ mice IL-27 responses also were ﬂawed. As
IL-27 suppresses differentiation of Th17 cells and promotes T cells to
secrete IL-10, defective IL-27 responses further promote a Th2 shift.
Additionally, IFN-I stimulation inhibits IL-23-dependent Th17 expan-
sion.52 As pointed out above, the currently known Th17 signature
cytokines IL-17A, IL-17F, IL-21 and IL-22 have not been found to have
a critical role in promoting the development of EAE. Instead, IL-23-
induced Th17 cells produce granulocyte macrophage colony-stimulat-
ing factor (GM-CSF) that seems to be important in conferring
disease.45 This cytokine stimulates invading myeloid cells, which in
turn promote and sustain inﬂammation within the CNS.53 For a
better understanding of how the IFN-beta stimulation of myeloid cells
affects their responsiveness to GM-CSF stimulation, additional studies
are necessary.
THERAPEUTIC POTENTIAL OF TREATMENT WITH RLH
LIGANDS
Similar to Ifnar1/ mice, Ips-1/ mice (also referred to as Cardif/,
Mavs/ or Visa/)54 devoid of the RLH system showed enhanced
autoimmune inﬂammatory disease of the CNS.55 By analogy to the
above-discussed experiments with Ifnar1/ mice, this observation
argues for the possibility that IFN-I responses induced by peripheral
RLH triggering might show some therapeutic effect. Indeed, disease
severity was markedly reduced in RIG-I or MDA5-stimulated mice.55
This therapeutic effect was only observed in IFN-I receptor-competent
mice, indicating that IFN-I is the key effector cytokine. Interestingly,
engagement of the IFN-I receptor on myeloid cells including mono-
cytes, macrophages, microglia or granulocytes did not account for the
suppression of CNS autoimmunity upon treatment with RLH ligands.
Instead, IFN-I receptor expression on DCs was essential under such
conditions (for a schematic depiction, compare Figures 1b and c).
Treatment with RLH ligands inhibited proliferation and induced
apoptosis of MOG3555-speciﬁc Th1 and Th17 cells. Of note,
the experimental data obtained so far do not support the idea that
RLH ligand treatment affects the frequency or the function of
CD4+Foxp3+Treg cells. Currently, the hypothesis that soluble factors
such as IFN-I and IL-27 secreted by RLH-stimulated DCs inhibit
encephalitogenic T-cell responses is favored. This was demonstrated in
mice with EAE disease showing a conditional deletion of the IFN-I
receptor on DCs that were no longer responsive to RLH ligand
treatment. On the contrary, mice with a conditional deletion of the
IFN-I receptor on myeloid cells showed even enhanced disease, as
observed earlier,46 and still responded to RLH ligand therapy. In
conclusion, IFN-I receptor engagement of DCs is crucially required to
confer therapeutic effects in the CNS, whereas IFN-I receptor engage-
ment of myeloid cells is not required. These observations are in
contrast to the disease-ameliorating effects of IFN-I responses induced
in the context of EAE pathogenesis, where IFN-I receptor triggering of
myeloid cells had a crucial role (for a schematic depiction, see
Figure 1). This can probably be explained by the fact that therapeutic
RLH ligand treatment elicits IFN-I responses primarily in peripheral
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Figure 1 Schematic depiction of the cellular mechanisms of endogenously induced versus therapeutically triggered type I interferon responses that modulate
Th1/Th17-mediated autoimmunity in the CNS. (a) In EAE, IFN-I receptor engagement of myeloid cells (MQ) is critical to ameliorate disease burden. (b, c)
Upon treatment with RLH ligands, therapeutic effects are (b) independent of IFN-I receptor triggering of myeloid cells (c) and dependent on IFN-I receptor
triggering of DCs.
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exclusively observed locally within the CNS. Of note, endogenous
IFN-I responses do not induce antibodies against IFN-I, thus ensuring
that the efﬁcacy of therapeutic RLH ligand treatment is maintained
even after repeated treatments.
PERSPECTIVES
Analysis of a rodent model of MS revealed the signiﬁcance of IFN-I in
ameliorating autoimmune inﬂammation within the CNS. Under such
conditions IFN-I receptor engagement of myeloid cells had a critical
role in improvement of the overall physical status. Future experiments
will reveal which myeloid cell subset, and whether perhaps other
professional antigen-presenting cells, has to be IFN-I receptor-triggered
in order to confer disease amelioration. Interestingly, RLH-deﬁcient
mice showed an as much enhanced autoimmune disease as IFN-I
receptor-deﬁcient mice, suggesting that RLH triggering might improve
disease. Indeed, peripheral treatment with complexed RNA of wild-
type mice with EAE disease induced a signiﬁcant overall improvement.
This effect was dependent on IFN-I triggering of DCs. Considering that
approximately 30% of MS patients under IFN-beta therapy develop
IFN-beta neutralizing antibody responses that reduce efﬁcacy of IFN-
beta treatment, the above-summarized results suggest that RLH
triggering might be a new strategy to induce IFN-I responses that
have an impact on MS and would not induce auto-antibody responses.
This is due to the fact that in vivo bioactive IFN-I is freshly produced
by stimulated cells and upon secretion is transported by the lymph or
the blood stream to the site of action. In the periphery, most of the
recirculating IFN-I is absorbed within the liver, resulting in a rapid
decay of bioactive IFN-I in the blood within 1–2 days. Before the RLH
ligand treatment concept can be further evaluated in patients, it will be
of interest to study whether RLH ligand treatment can be modiﬁed in a
manner that IFN-I responses within the CNS are selectively triggered.
New RLH ligand formulations might be helpful in reaching this
objective. RLH ligand treatment of DCs induces IFN-beta as well as
IFN-alpha responses. Therefore it might be interesting to study
whether RLH ligands can be modiﬁed in such a way that only IFN-
beta or IFN-alpha responses are elicited and whether both responses
would show a similar impact on the disease course. Furthermore,
speciﬁc targeting of relevant antigen-presenting cells by RLH ligand
treatment might be attractive because such a strategy probably would
induce less fulminant cytokine responses which would cause reduced
overall adverse effects. A detailed analysis of DC-mediated effects that
affect the balance between Th1/Th17 and Th2 responses and disease
severity would help to further reﬁne potential therapeutic strategies. In
conclusion, the recent observation that RLH ligand treatment has an
ameliorating effect on autoimmune inﬂammation of the CNS in a
rodent model might pave the way for new therapeutic strategies of MS
by inducing endogenous IFN-I responses.
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